In conclusion, our data suggest that high levels of ITGB1 and its overactivation may represent a biomarker of tumor invasion and progression after prolonged therapy with osimertinib and also with inhibitors of MAPK pathway like selumetinib. Here, ITGB1 is linked to neoplasm.